HCV
FDA warns three Hepatitis C drugs may worsen liver function in some rare cases
August 29, 2019Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health
The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …
FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)
May 1, 2019Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma
The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 …
AbbVie’s case against the NHS thrown out of court
January 22, 2019Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health
A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court. Mr Justice …
New hepatitis C combo boasts 97% cure rate for just $300
April 12, 2018Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi
A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …
Contaminated blood inquiry to probe thousands of deaths
July 12, 2017Medical Communications, Research and Development HCV, HIV, biotech, drugs, haemophilia, pharma, pharmaceutical
UK Government has announced that it will launch an inquiry to discover how 4,670 people were given blood infected by …
Gilead says US FDA approves Epclusa to treat hepatitis C
June 29, 2016Research and Development, Sales and Marketing Epclusa, Gilead, HCV, US FDA, drug approval, regulation
US drug firm Gilead Sciences (Nasdaq: GILD) said the US Food and Drug Administration has approved its Epclusa (sofosbuvir/velpatasvir), in …
Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials
April 14, 2016Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier
US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …
Charity challenges Sovaldi patent
February 10, 2015Sales and Marketing Gilead, HCV, Médecins du Monde, sofosbuvir, sovaldi, world health organization
Doctors of the World (also known as Médecins du Monde) has filed an opposition to the patent for Gilead’s blockbuster …
New drug added to generic Sovaldi licensing
January 26, 2015Manufacturing and Production, Sales and Marketing Gilead, HCV, hepatitis C, sofosbuvir, sovaldi
Gilead has expanded the licensing of generic versions of its blockbuster hepatitis C treatment Sovaldi to include a new experimental …
Gilead gets Harvoni boost for Europe
November 20, 2014Sales and Marketing EU, Gilead, HCV, harvoni, hepc, ledipasvir, sofosbuvir, svaldi
Gilead Sciences’ new hepatitis C (HCV) tablet Harvoni has been approved across the European Union to treat the majority of …
BMS claims advance with hepatitis C regimen
November 10, 2014Research and Development, Sales and Marketing BMS, Gilead, HCV, dcv-trio, hep C, hepatitis C, liver, sovaldi
Bristol-Myers Squibb has reported data for its hepatitis C virus cocktail that it says outperforms even newer all-oral therapies in …
BMS pulls hep C combo treatment in US
October 7, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Combo, HCV, asunaprevir, daclatasvir, hep C, sovaldi
Bristol-Myers Squibb will not attempt to bring its new combination hepatitis C treatment to the US market given the current …
Sovaldi combo sees CHMP green light
September 29, 2014Sales and Marketing CHMP, EU, Gilead, HCV, harvoni, hep C, sovaldi
The CHMP is recommending that Gilead’s new combination hepatitis C drug therapy Harvoni should be approved for use across the …
CHMP approves six drugs including daclatasvir
June 30, 2014Sales and Marketing BMS, CHMP, HCV, Plavix, daclatasvir, daklinza, ge
A key advisory committee for the European Medicines Agency has given its approval to six new drugs at its latest …
Boehringer abandons hep C
June 23, 2014Research and Development, Sales and Marketing AbbVie, Boehringer, HCV, faldaprevir, german, hep C
Boehringer Ingelheim has abandoned its hepatitis C (HCV) drug development programme as a dead loss after ‘re-evaluating’ its strategy. The …
